title: Consensus statement on the use of intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke by the Chinese Stroke Therapy Expert Panel.
abstract: BACKGROUND
  The last update of the consensus statement on intravenous recombinant tissue plasminogen activator (IV rt-PA) for acute ischemic stroke (AIS) by the Chinese Stroke Therapy Expert Panel was published in 2006. Great progress has been made since then.
  
  
  OBJECTIVE
  To provide another update on the new knowledge of IV rt-PA for AIS since 7 years ago.
  
  
  METHODS
  In summer of 2012, the Chinese Stroke Therapy Expert Panel was reconvened. New publications on the use of IV rt-PA for AIS were reviewed. In addition, all newly published consensus and guidelines from other countries were reviewed. The 2006 version of Chinese Consensus was then updated.
  
  
  RESULTS
  There is now clinical evidence to support the use of IV rt-PA between 3 and 4.5 h after the onset with several exclusion criteria. More studies are needed to provide the evidence for IV rt-PA use beyond 4.5 h. There is benefit giving IV rt-PA within 3 h to patients who are older than 80 and in patients with ongoing atrial fibrillation. Patients with INR<1.7 while on warfarin, minor strokes, rapid improving strokes and severe strokes should be treated and can all be benefited from IV rt-PA.
  
  
  CONCLUSIONS
  Since IV rt-PA was initially recommended in 1996, there is now more evidence support its use, efficacy and safety. The treatment time window is also being expanded. More public education on stroke recognition are needed so many stroke patients may benefit from the treatment.
  
  
  CONCLUSIONS
  The 2013 version of Chinese IV rt-PA consensus contains the most up-to-date information on the use of IV rt-PA for AIS. It will be a useful tool and guideline to provide appropriate thrombolytic therapy to stroke patients who meet the criteria.
authors.affiliation: Department of Neurology, The First Affiliated Hospital, Jinan University Guangzhou, Guangzhou, China. andingxu@gmail.com
authors.forename: An-Ding
authors.initials: AD
authors.lastname: Xu
authors.forename: Yong-Jun
authors.initials: YJ
authors.lastname: Wang
authors.forename: David Z
authors.initials: DZ
authors.lastname: Wang
mesh_terms: D006801:Humans; D044466:Asian People; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D007275:Injections, Intravenous; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator
keywords: Acute ischemic stroke; Consensus; Fibrinolysin; Tissue plasminogen activator